TG Therapeutics, Inc.

Contributing Author

Recent Articles by TG Therapeutics, Inc.

Nov-03	TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance TGTX GlobeNewswire
Oct-31	TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update TGTX GlobeNewswire
Oct-28	TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI TGTX GlobeNewswire
Sep-24	New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment TGTX GlobeNewswire
Sep-10	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting TGTX GlobeNewswire
Sep-08	TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment TGTX GlobeNewswire
Sep-04	TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference TGTX GlobeNewswire
Sep-03	TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program TGTX GlobeNewswire
Aug-28	TG Therapeutics to Participate in the Cantor Global Healthcare Conference TGTX GlobeNewswire
Aug-04	TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance TGTX GlobeNewswire
Jul-30	TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update TGTX GlobeNewswire
Jun-06	TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference TGTX GlobeNewswire
Jun-02	TG Therapeutics to Participate in the Jefferies Global Healthcare Conference TGTX GlobeNewswire
May-30	TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting TGTX GlobeNewswire
May-27	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting TGTX GlobeNewswire
May-05	TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance TGTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.